NCT03447470 2025-01-29
Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies
Redx Pharma Ltd
Phase 1 Completed
Redx Pharma Ltd
National Institutes of Health Clinical Center (CC)
Sumitomo Pharma America, Inc.
M.D. Anderson Cancer Center
Stanford University
National Institutes of Health Clinical Center (CC)